Abstract:Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. The intricate NAFLD pathogenesis is summarized by the multiple-hits hypothesis, which combines all the environmental and genetic factors that promote the development of NAFLD into a single scenario. Among these, bacterial lipopolysaccharides (LPS) are derived from the overgrowth of Gram-negative bacteria and translocated mainly as a consequence of enhanced intestinal permeability. Furthermore, oxidative stress is increased in NAFLD as a consequence of reactive oxygen species (ROS) overproduction and a shortage of endogenous antioxidant molecules, and it is promoted by the interaction between LPS and the Toll-like receptor 4 system. Interestingly, oxidative stress, which has previously been described as being overexpressed in cardiovascular disease, could represent the link between LPS and the increased cardiovascular risk in NAFLD subjects. To date, the only effective strategy for the treatment of NAFLD and non-alcoholic steatohepatitis (NASH) is the loss of at least 5% body weight in overweight and/or obese subjects. However, the dose-dependent effects of multispecies probiotic supplementation on the serum LPS level and cardiometabolic profile in obese postmenopausal women were demonstrated. In addition, many antibiotics have regulatory effects on intestinal microbiota and were able to reduce serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and tumor necrosis factor alpha (TNF-α) in NASH animal models. Regarding the oxidant status, a Mediterranean diet has been reported to reduce oxidant stress, while vitamin E at high daily dosages induced the resolution of NASH in 36% of treated patients. Silymarin had the positive effect of reducing transaminase levels in NAFLD patients and long-term treatment may also decrease fibrosis and slow liver disease progression in NASH. Finally, the influence of nutraceuticals on gut microbiota and oxidant stress in NAFLD patients has not yet been well elucidated and there are insufficient data either to support or refuse their use in these subjects.

Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy

Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease.

The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD

Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease

Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review

Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease

Oxidative stress in nonalcoholic fatty liver disease: a reappraisal of the role in supporting inflammatory mechanisms

Research Progress on the Mechanism of Traditional Chinese Medicine in the Treatment of Non-Alcoholic Fatty Liver Disease Based on Oxidative Stress

Role of Oxidative Stress and Lipid Peroxidation in the Pathophysiology of NAFLD

Endoplasmic Reticulum Stress and Lipophagy in Nonalcoholic Steatohepatitis

New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress

Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship

Mitochondrial Oxidative Stress and Antioxidants Balance in Fatty Liver Disease

NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook

Oxidative Stress in Liver Pathophysiology and Disease

Role of Endoplasmic Reticulum Stress in the Pathogenesis of Nonalcoholic Fatty Liver Disease

Involvement of Xanthine Oxidase and Paraoxonase 1 in the Process of Oxidative Stress in Nonalcoholic Fatty Liver Disease.

Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis

Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease

The Role of Oxidative Stress and Antioxidants in Liver Diseases

Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective.